Toni Choueiri

Key takeaways

Toni Choueiri belongs to astronomy; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Toni Choueiri to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Toni Choueiri from memory before moving on to harder problems.

Reference excerpt

Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in advanced renal cell carcinoma (RCC). Choueiri also co-established the International metastatic database Consortium with Daniel Heng. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

Early life and education Choueiri was born and raised in Beirut, Lebanon where he remained for his medical degree at Saint Joseph University's Faculty of Medicine. He trained at the Cleveland Clinic in Ohio after his medical school and moved in 2007 to the Dana–Farber Cancer Institute.

Career Choueiri collaborated with Paul L. Nguyen in 2011 to perform a meta-analysis of randomized studies involving 4,141 prostate cancer patients to conclude whether men receiving ADT had a higher rate of cardiovascular deaths. The conclusion of the study found that there was no difference between those who received ADT compared with those who didn't but could not rule out that ADT might elevate the risk of fatal heart attacks. The following year, Choueiri found that three new cancer drugs were linked to a slightly elevated chance of fatal side effects. From 2015 and for the next several years, Choueiri led the development of cabozantinib in metastatic RCC from early phase 1 to randomized trials leading to its approval in TKI-refractory disease in 2016 and in untreated RCC patients in 2017. Choueiri also co-established the International metastatic database Consortium with Daniel Heng. In 2017, Choueiri led a study which found that patients with metastatic papillary renal cell carcinoma benefited from savolitinib, a drug targeted to an abnormal genetic pathway causing cancerous growth. The following year, Choueiri was appointed full professor of medicine at Harvard Medical School and continued in his position as the director of the Lank Center for Genitourinary Oncology. In this role, he led the development of the combination of axitinib+avelumab from phase I to late stage trials, leading to the combination being approved for RCC therapy in May 2019. During the COVID-19 pandemic in North America, Choueiri completed shifts with the COVID-19 service team, treating oncology patients who have either been diagnosed COVID-19 positive, or who are suspected of being COVID-19 positive. In an effort to combat COVID, he co-led a multinational study to identify risk factors unique to cancer patients. He also continued his research into kidney cancer and developed, with Matthew Freedman, one of the first liquid biopsy methods which could detect early stages of kidney cancers with high accuracy. The test was nearly 100 per cent accurate when used with blood samples to distinguish patients with kidney cancer from those without. Similarly, Choueiri also collaborated with William Kaelin Jr. in translational and clinical research, specifically around HIF2 inhibitors in clear-cell renal cancers. In January 2021, the Food and Drug Administration (FDA) approved nivolumab, an immunotherapy drug, with cabozantinib for advanced renal cell carcinoma treatment. He also co-led with Robert Motzer the development of the combination of Lenvatinib+pembrolizumab which was FDA approved in August 2021. Later that year, Choueiri revealed the results of his KEYNOTE-564 trial, which showed for the first time that immunotherapy can be efficacious in the adjuvant setting in high-risk renal cancer (RRC). This culminated in the FDA's approval of pembrolizumab in RCC after surgery. That drug, later called Belzutifan, was FDA approved based on LITESPARK-005 trial that Choueiri led. As a result of his research, Choueiri was inducted in the 2021 Giants of Cancer Care class and received the King Hussein Cancer Research Lifetime Achievement Award- International Track. He was also inducted as a member into the American Society for Clinical Investigation. In 2024, Choueiri and Dana-Farber scientist Catherine J. Wu oversaw phase 1 of a clinical trial to test the effectiveness of personalized cancer vaccines on kidney cancer. Their results found that neoantigen-derived personalized cancer vaccines were capable of targeting key driver mutations in kidney cancer, which can then induce anti-cancer immunity. All nine of their clinical trial patients generated a successful anti-cancer immune response after they received the vaccine. In recognition of his continued efforts to combat cancer, Choueiri was awarded the Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. In 2026, FDA approval was granted to the combination of pembrolizumab and Belzutifan based on Choueiri’s work combining targets and drugs from the 2018 and 2019 Nobel Prizes in Medicine.

Personal life Choueiri and his wife Sue have two children together and are soccer fans of the MLS, Bundesliga, and Premier League.

References

External links Toni Choueiri publications indexed by Google Scholar CV

Illustrations

Worked examples

Example 1 — a first encounter with Toni Choueiri

Start with the simplest possible case. Write down what Toni Choueiri claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In astronomy, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Toni Choueiri before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Toni Choueiri ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Toni Choueiri

In research: Toni Choueiri appears in astronomy research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Toni Choueiri in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Toni Choueiri is common in secondary-school and first-year university syllabi. It links to neighbouring topics American oncologists, Harvard Medical School faculty, Lebanese medical researchers, so understanding it makes those chapters shorter.
In everyday life: Look for Toni Choueiri outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Toni Choueiri in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Toni Choueiri means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Toni Choueiri out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Toni Choueiri in simple terms?

Toni K. Choueiri is a Lebanese American medical oncologist and researcher.

Why does Toni Choueiri matter?

Because it connects several astronomy ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Toni Choueiri?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Toni Choueiri.